Meeting Report

2020–2021 Drug Updates in Solid Tumors

Christine Cambareri, PharmD, BCPS, BCOP, CSP

From University of Pennsylvania Abramson Cancer Center, Philadelphia, Pennsylvania

Presenter’s disclosure of conflicts of interest is found at the end of this article.


J Adv Pract Oncol 2022;13(3):275–281 | https://doi.org/10.6004/jadpro.2022.13.3.19 | © 2022 Harborside™


  

ABSTRACT

During JADPRO Live Virtual 2021, Christine Cambareri, PharmD, BCPS, BCOP, CSP, briefed advanced practitioners on drugs and biologics that were approved for the treatment of solid tumors from late 2020 to late 2021, including their adverse event profiles. The trend of more oral dosage forms and the significant number of checkpoint inhibitors approved points towards changing treatment paradigms in the field.




For access to the full length article, please sign in.

Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
Copyright © 2010-2022 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.